MOUNJARO 5 mg PRE-FILLED PEN INJECTION SOLUTION

Introduction

Package Leaflet: Information for the Patient

Mounjaro 2.5mg solution for injection in a pre-filled pen

Mounjaro 5mg solution for injection in a pre-filled pen

Mounjaro 7.5mg solution for injection in a pre-filled pen

Mounjaro 10mg solution for injection in a pre-filled pen

Mounjaro 12.5mg solution for injection in a pre-filled pen

Mounjaro 15mg solution for injection in a pre-filled pen

tirzepatide

This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of the package leaflet contains information on how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.

• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is Mounjaro and what is it used for
2. What you need to know before you use Mounjaro
3. How to use Mounjaro
4. Possible side effects
5. Storage of Mounjaro
6. Contents of the pack and other information

1. What is Mounjaro and what is it used for

Mounjaro contains the active substance tirzepatide and is used to treat adults with type 2 diabetes mellitus. Mounjaro lowers blood sugar levels only when blood sugar levels are high.

Mounjaro is also used to treat adults with obesity or overweight (with a BMI of at least 27 kg/m2). Mounjaro affects appetite regulation, which can help you eat less food and reduce your body weight.

In type 2 diabetes, Mounjaro is used:

• alone when you cannot take metformin (another diabetes medicine).
• or in combination with other diabetes medicines when these are not enough to control the sugar levels in your blood. These other medicines may be taken by mouth and/or may be an insulin injection.

Mounjaro is also used together with diet and exercise to lose weight and help keep weight under control in adults who have:

• a BMI of 30 kg/m² or more (obesity) or
• a BMI of at least 27 kg/m², but less than 30 kg/m² (overweight) and weight-related health problems (such as prediabetes, type 2 diabetes, high blood pressure, abnormal fat levels in the blood, breathing problems during sleep called "obstructive sleep apnea" or a history of heart attack, stroke, or vascular problems)

Body Mass Index (BMI) is a measure of your weight in relation to your height.

In patients with obstructive sleep apnea (OSA) and obesity, Mounjaro can be used with or without positive airway pressure (PAP) therapy.

It is important that you follow the advice about your diet and physical activity given by your doctor, nurse, or pharmacist.

2. What you need to know before you use Mounjaro

Do not use Mounjaro

• if you are allergic to tirzepatide or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before starting Mounjaro if:

• you have severe problems with digestion of food or food stays in your stomach for too long (including severe gastroparesis).
• you have ever had pancreatitis (inflammation of the pancreas, which can cause severe pain in the stomach and back that does not go away).
• you have any problems with your eyes (diabetic retinopathy or macular edema).
• you are taking a sulfonylurea (another diabetes medicine) or insulin for diabetes, as low blood sugar (hypoglycemia) may occur. Your doctor may need to adjust the dose of these medicines to reduce this risk.

When starting treatment with Mounjaro, you may experience fluid loss/dehydration, such as vomiting, nausea, and/or diarrhea, which can lead to a decrease in kidney function. To avoid dehydration, it is essential to drink plenty of fluids. Contact your doctor if you have any questions or concerns.

If you know you are going to have surgery where you will be put under anesthesia (put to sleep), tell your doctor that you are taking Mounjaro.

Children and adolescents

This medicine must not be used in children and adolescents under 18 years because it has not been studied in this age group.

Other medicines and Mounjaro

Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.

Pregnancy

If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. This medicine must not be used during pregnancy as the effects of this medicine on the fetus are not known. Therefore, it is recommended to use contraceptive methods while using this medicine.

Breast-feeding

It is not known whether tirzepatide passes into breast milk. A risk to newborns/babies cannot be ruled out. If you are breast-feeding or plan to breast-feed, consult your doctor before using this medicine. You and your doctor must decide whether to stop breast-feeding or stop using Mounjaro.

Driving and using machines

This medicine is unlikely to affect your ability to drive or use machines. However, if you use Mounjaro with a sulfonylurea or insulin, low blood sugar (hypoglycemia) may occur, which can reduce your ability to concentrate. Avoid driving or using machines if you have any signs of low blood sugar, such as headache, drowsiness, weakness, dizziness, hunger, confusion, irritability, rapid heartbeat, and sweating (see section 4). See section 2, "Warnings and precautions" for information on the increased risk of having low blood sugar. Consult your doctor for more information.

Mounjaro contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially "sodium-free".

3. How to use Mounjaro

Follow the instructions for administration of this medicine exactly as told by your doctor or pharmacist. If you are not sure, ask your doctor or pharmacist again.

How much to use

• The initial dose is 2.5 mg once a week for four weeks. After four weeks, your doctor will increase your dose to 5 mg once a week.

• Your doctor may increase your dose in increments of 2.5 mg up to 7.5 mg, 10 mg, 12.5 mg, or 15 mg once a week if needed. In each case, your doctor will tell you to stay on a specific dose for at least 4 weeks before moving to a higher dose.

Do not change your dose unless your doctor tells you to.

Each pen contains a dose of Mounjaro of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg.

When to use Mounjaro

You can use your pen at any time of the day, with or without food. If possible, you should use it on the same day each week. To help you remember when to use Mounjaro, you can write down the day of the week when you inject your first dose on the carton of your pen or on a calendar.

If necessary, you can change the day of your weekly Mounjaro injection, as long as at least 3 days have passed since your last injection. After selecting a new dosing day, continue with once-weekly administration on that new day.

How to inject Mounjaro

Mounjaro is injected under the skin (subcutaneous injection) in the abdomen area at least 5 cm away from the navel or in the upper thigh or upper arm. You may need help from another person if you want to inject into the upper arm.

If you want, you can inject into the same area of your body each week. However, make sure to choose different injection sites within the same area. If you also inject insulin, choose a different injection site for that injection.

Before using Mounjaro, carefully read the "Instructions for use" of the pen.

Monitoring of blood sugar levels

If you are using Mounjaro with a sulfonylurea or insulin, it is essential to monitor your blood sugar levels as instructed by your doctor, pharmacist, or nurse (see section 2, "Warnings and precautions").

If you use more Mounjaro than you should

If you use more Mounjaro than you should, talk to your doctor immediately. Too much medicine may cause your blood sugar levels to drop too low (hypoglycemia) and may also cause nausea or vomiting.

If you forget to use Mounjaro

If you miss an injection and,

• it has been 4days or less since you should have used Mounjaro, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.
• it has been more than 4days since you should have used Mounjaro, skip the missed dose. Then inject your next dose as usual on your scheduled day.

Do not inject a double dose to make up for a missed dose. The minimum time between two doses must be at least 3 days.

If you stop using Mounjaro

Do not stop using Mounjaro without talking to your doctor. If you stop using Mounjaro and have type 2 diabetes, your blood sugar levels may increase.

If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Uncommon(may affect up to 1 in 100 people)

• Pancreatitis (inflammation of the pancreas) that could cause severe stomach and back pain that does not go away. See your doctor immediately if you experience these symptoms.

Rare(may affect up to 1 in 1,000 people)

• Severe allergic reactions (e.g., anaphylactic reaction, angioedema). You should get medical help immediately and tell your doctor if you experience symptoms such as breathing problems, rapid swelling of the lips, tongue, and/or throat with difficulty swallowing and rapid heartbeat.

Other side effects

Very common(may affect more than 1 in 10 people)

• Nausea
• Diarrhea
• Stomach pain (abdominal pain) reported in patients treated for weight control
• Vomiting reported in patients treated for weight control
• Constipation reported in patients treated for weight control

These side effects are usually not serious. Nausea, diarrhea, and vomiting are more common when starting Mounjaro but decrease over time in most patients.

• Low blood sugar (hypoglycemia) is very common when tirzepatide is used with sulfonylurea and/or insulin. If you are taking a sulfonylurea or insulin for type 2 diabetes, you may need to have your dose reduced while using tirzepatide (see section 2, "Warnings and precautions"). Symptoms of low blood sugar can include headache, drowsiness, weakness, dizziness, hunger, confusion, irritability, rapid heartbeat, and sweating. Your doctor should tell you how to treat low blood sugar levels.

Common(may affect up to 1 in 10 people)

• Low blood sugar (hypoglycemia) when tirzepatide is used for type 2 diabetes with metformin together with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (another diabetes medicine)
• Allergic reaction (hypersensitivity) (e.g., rash, itching, and eczema)
• Dizziness reported in patients treated for weight control
• Low blood pressure reported in patients treated for weight control

• Decreased appetite reported in patients treated for type 2 diabetes
• Stomach pain (abdominal pain) reported in patients treated for type 2 diabetes
• Vomiting reported in patients treated for type 2 diabetes – usually decreases over time
• Indigestion (dyspepsia)
• Constipation reported in patients treated for type 2 diabetes
• Bloating
• Belching
• Gas (flatulence)
• Acid reflux or heartburn (also called gastroesophageal reflux disease – GERD) – a disease caused by stomach acid flowing back up into the tube that connects the stomach to the mouth

• Hair loss reported in patients treated for weight control
• Fatigue
• Injection site reactions (e.g., itching or redness)
• Rapid heartbeat
• Increased levels of pancreatic enzymes (such as lipase and amylase) in the blood
• Increased levels of calcitonin in the blood in patients treated for weight control.

Uncommon(may affect up to 1 in 100 people)

• Low blood sugar (hypoglycemia) when tirzepatide is used with metformin for type 2 diabetes
• Gallstones
• Gallbladder inflammation
• Weight loss reported in patients treated for type 2 diabetes
• Pain at the injection site
• Increased levels of calcitonin in the blood in patients treated for type 2 diabetes or for OSA with obesity
• Altered sense of taste
• Changes in skin sensitivity
• Delayed emptying of the stomach

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Mounjaro

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label of the pen and on the carton after EXP. The expiry date is the last day of the month shown.

Store in a refrigerator (2°C to 8°C). Do not freeze. If the pen has been frozen, DO NOT USE IT.

Store in the original package to protect from light.

Mounjaro can be stored without refrigeration below 30°C for up to 21 consecutive days, after which the pen must be discarded.

Do not use this medicine if you notice that the pen is damaged or the medicine is cloudy, has color, or contains particles.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Contents and Additional Information

Mounjaro Composition

The active ingredient is tirzepatida.

• Mounjaro 2.5mg:Each pre-filled pen contains 2.5 mg of tirzepatida in 0.5 ml of solution (5 mg/ml).
• Mounjaro 5mg:Each pre-filled pen contains 5 mg of tirzepatida in 0.5 ml of solution (10 mg/ml).
• Mounjaro 7.5mg:Each pre-filled pen contains 7.5 mg of tirzepatida in 0.5 ml of solution (15 mg/ml).
• Mounjaro 10mg:Each pre-filled pen contains 10 mg of tirzepatida in 0.5 ml of solution (20 mg/ml).
• Mounjaro 12.5mg:Each pre-filled pen contains 12.5 mg of tirzepatida in 0.5 ml of solution (25 mg/ml).
• Mounjaro 15mg:Each pre-filled pen contains 15 mg of tirzepatida in 0.5 ml of solution (30 mg/ml).

The other components are disodium hydrogen phosphate heptahydrate (E339), sodium chloride, sodium hydroxide (for more information, see section 2 "Mounjaro contains sodium"), concentrated hydrochloric acid, and water for injectable preparations.

Product Appearance and Container Contents

Mounjaro is a clear, colorless to slightly yellowish injectable solution in a pre-filled pen.

The pre-filled pen has a hidden needle that will automatically be inserted into the skin when the injection button is pressed. The pre-filled pen will retract the needle when the injection is complete.

Each pre-filled pen contains 0.5 ml of solution.

The pre-filled pen is for single use.

Container sizes are 2 pre-filled pens, 4 pre-filled pens, or a multiple pack of 12 (3 packs of 4) pre-filled pens. Not all pack sizes may be marketed.

Marketing Authorization Holder

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Netherlands.

Manufacturer

Eli Lilly Italia S.p.A., Via Gramsci 731/733, 50019, Sesto Fiorentino, Florence (FI), Italy.

Lilly France, 2, rue du Colonel Lilly, 67640 Fegersheim, France

You can request more information about this medicinal product from the local representative of the marketing authorization holder:

Date of Last Revision of this Prospectus:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu, and on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

Important Information You Should Know Before Injecting Mounjaro.

Read these instructions for use and the prospectus before using your Mounjaro pre-filled pen and each time you get a new pen.There may be new information. This information does not replace the conversation with your doctor, nurse, or pharmacist about your medical condition or treatment.

Consult your doctor, nurse, or pharmacist about how to properly inject Mounjaro.

• Mounjaro is a single-dose pre-filled pen.
• The pen has a hidden needle that will automatically be inserted into your skin when you press the injection button. The pre-filled pen will retract the needle when the injection is complete.
• Mounjaro is used once a week.
• It is injected only under the skin (subcutaneously).
• You or another person can inject it into the abdomen area, the top of the thigh, or the top of the arm.
• You may need the help of another person if you want to inject it into the top of the arm.

Parts of the Pen

Preparing to Inject Mounjaro

Choose Your Injection Site

Your doctor, nurse, or pharmacist can help you choose the best injection site for you.

• Country of registration
  Spain
• Active substance
  tirzepatide
• Prescription required
  Yes
• Manufacturer
  Eli Lilly Nederland B.V.
• This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
• Alternatives to MOUNJARO 5 mg PRE-FILLED PEN INJECTION SOLUTION
  MOUNJARO 10 mg PRE-FILLED PEN INJECTION SOLUTION

  Dosage form: INJECTABLE, 10 mg

  Active substance: tirzepatide

  Manufacturer: Eli Lilly Nederland B.V.

  Prescription required

  MOUNJARO 10 mg INJECTABLE SOLUTION IN VIAL

  Dosage form: INJECTABLE, 10 mg

  Active substance: tirzepatide

  Manufacturer: Eli Lilly Nederland B.V.

  Prescription required

  MOUNJARO 10 mg/dose KwikPen prefilled pen injector solution

  Dosage form: INJECTABLE, 10 mg/dose

  Active substance: tirzepatide

  Manufacturer: Eli Lilly Nederland B.V.

  Prescription required

Online doctors for MOUNJARO 5 mg PRE-FILLED PEN INJECTION SOLUTION

Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MOUNJARO 5 mg PRE-FILLED PEN INJECTION SOLUTION – subject to medical assessment and local rules.

0.0(1)

Tomasz Grzelewski

Dermatology20 years of experience

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

• seasonal and perennial allergies
• allergic rhinitis and chronic nasal symptoms
• asthma and breathing difficulties
• food and medication allergies
• urticaria, atopic dermatitis and skin reactions
• recurrent infections in children
• sports-related health questions
• general family medicine concerns

Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.

Book a video appointment

€80

Today11:55

Today12:20

Today12:45

Today13:10

Today13:35

More times

5.0(8)

Iryna Reznychenko

Gynecology25 years of experience

Dr Iryna Reznychenko is an obstetrician-gynaecologist, paediatric gynaecologist, and certified lactation consultant. She provides online consultations for women at all stages of life – from adolescence to menopause. Her work combines medical care for gynaecological conditions with dedicated support for breastfeeding challenges, both physical and emotional.

Areas of expertise:

• interpretation of test results and personalised treatment planning
• menstrual irregularities, PCOS, endometriosis
• abnormal uterine bleeding, endometrial hyperplasia, cervical dysplasia
• care during perimenopause and menopause, hormonal balance, cancer prevention
• breastfeeding issues: nipple pain, cracked skin, blocked ducts, low milk supply
• support during the postpartum and lactation period

Dr Reznychenko offers a clear, attentive and professional approach. Her consultations help prevent minor discomforts from developing into more serious concerns – all in a convenient online format.

Book a video appointment

€50

Today12:25

Today13:15

Today14:05

Today14:55

Today15:45

More times

5.0(25)

Anna Biriukova

General medicine5 years of experience

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

• High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
• Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
• Leg swelling, chronic fatigue, reduced exercise tolerance.
• EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
• Post-COVID-19 cardiac monitoring and care.

Endocrinology – Diabetes, thyroid, metabolism:

• Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
• Individual treatment plans including oral medications and insulin therapy.
• GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
• Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
• Metabolic syndrome – obesity, lipid disorders, insulin resistance.

Gastroenterology – Digestive health:

• Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
• Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
• Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).

General internal medicine and preventive care:

• Respiratory infections – cough, colds, bronchitis.
• Lab test analysis, therapy adjustments, medication management.
• Adult vaccinations – planning, contraindications assessment.
• Cancer prevention – screening strategies and risk assessment.
• Holistic approach – symptom relief, complication prevention, and quality of life improvement.

Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.

Book a video appointment

€60

December 2414:00

December 2414:50

December 2415:40

December 2416:30

December 2507:00

More times

5.0(8)

Mar Tabeshadze

Endocrinology10 years of experience

Dr. Mar Tabeshadze is a licensed endocrinologist and general practitioner in Spain. She provides online consultations for adults, offering medical support for a wide range of endocrine conditions and related health concerns.

• Diagnostic consultations for suspected endocrine disorders
• Management of thyroid conditions, including in pregnant women
• Early detection and treatment of type 1 and type 2 diabetes, with personalised therapy plans
• Obesity treatment: identifying underlying causes of weight gain, combining medication and non-pharmacological strategies, and long-term support
• Diagnosis and treatment of endocrine-related skin, hair, and nail issues
• Ongoing care for patients with osteoporosis, pituitary, and adrenal gland disorders

Dr. Tabeshadze takes a patient-centred approach based on evidence-based medicine. Her goal is to help patients achieve hormonal balance, manage chronic conditions effectively, and improve overall well-being through targeted, personalised care.

Book a video appointment

€55

December 2511:00

December 2611:00

December 2911:00

December 3011:00

December 3111:00

More times

5.0(12)

Dmytro Horobets

Family medicine6 years of experience

Dr. Dmytro Horobets is a licensed family medicine physician in Poland, specialising in endocrinology, diabetology, obesity management, gastroenterology, pediatrics, general surgery, and pain medicine. He offers online consultations for adults and children, providing personalised medical support for a wide range of acute and chronic health concerns.

Areas of expertise:

• Endocrinology: diabetes type 1 and type 2, prediabetes, thyroid disorders, metabolic syndrome, hormonal imbalance.
• Obesity medicine: structured weight management plans, nutritional counselling, obesity-related health risks.
• Gastroenterology: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), liver and biliary conditions.
• Pediatric care: infections, respiratory symptoms, digestive issues, growth and development monitoring.
• General surgery support: pre- and post-surgical consultations, wound care, rehabilitation.
• Pain management: chronic and acute pain, back pain, joint pain, post-traumatic pain syndromes.
• Cardiovascular health: hypertension, cholesterol control, risk assessment for heart disease.
• Preventive medicine: regular check-ups, health screenings, long-term management of chronic conditions.

Dr. Horobets combines evidence-based medicine with a patient-centred approach. He carefully evaluates each patient’s medical history and symptoms, offering clear explanations and structured treatment plans adapted to individual needs.

Whether you need help managing diabetes, tackling weight-related health issues, interpreting lab results, or receiving general family medicine support, Dr. Horobets provides professional online care tailored to your specific health goals.

Book a video appointment

€60

December 2709:00

December 2709:30

January 309:00

January 309:30

January 1009:00

More times

0.0(2)

Marianna Neshta

Endocrinology24 years of experience

Marianna Neshta is a medical doctor specialising in endocrinology and ultrasound diagnostics. She provides online consultations for adults, focusing on the diagnosis, treatment, and long-term management of endocrine disorders. Her approach includes personalised care plans, analysis of lab results and ultrasound scans, and evidence-based treatment.

Key areas of expertise:

• Type 1 and Type 2 diabetes – diagnosis, therapy adjustment, CGM interpretation, and prevention of chronic complications
• Obesity – treatment using both medication and lifestyle strategies, including modern GLP-1 medications and tailored follow-up plans
• Thyroid disorders – ultrasound assessment, treatment planning, and management during pregnancy
• Male hypogonadism – age-related or hormonal, including diagnostics and therapy
• Metabolic syndrome, prediabetes, lipid disorders – risk assessment, lifestyle recommendations, and medical treatment
• Calcium metabolism disorders – diagnosis and management of osteoporosis, hyperparathyroidism, and hypoparathyroidism

Dr Neshta applies current clinical guidelines and diagnostic tools, offering medical support adapted to each patient’s individual needs — all in an accessible online format.

Book a video appointment

€45

December 2717:00

December 2717:45

January 317:00

January 317:45

January 1017:00

More times

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Subscribe

Follow us on social media